PNC-27 (30mg) Dosage Protocol
PNC-27 is a synthetic peptide containing a p53 binding domain and a cell-penetrating sequence. Research suggests it may selectively target cancer cells that overexpress HDM-2.
Add 3.0 mL bacteriostatic water → 10 mg/mL
1-3 mg per injection for research
At 10 mg/mL: 10 units = 1 mg, 30 units = 3 mg
Lyophilized: -20°C; Reconstituted: 2-8°C for up to 2 weeks
| Week | Daily Dose | Units (per injection) |
|---|---|---|
| Research protocols | 1-3 mg daily | 10-30 units |
| Frequency | Daily or EOD | Per research design |
| Duration | Variable | Per study protocol |
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe
- 2Inject slowly down the vial wall
- 3Gently swirl until fully dissolved
- 4Label with date and concentration, refrigerate immediately
PNC-27 contains a p53 binding domain that interacts with HDM-2, which is overexpressed in many cancer cells. The peptide also contains a membrane-penetrating sequence. Research suggests it may selectively induce necrosis in cancer cells while sparing normal cells.
- Selective cancer cell targeting
- Research in oncology applications
- May spare normal cells
- Novel mechanism of action
- Kanovsky M, et al. Peptides from p53 transactivation domain. Proc Natl Acad Sci. 2001
- PNC-27 cancer cell research studies
- HDM-2 targeting peptide research
Lyophilized
Store at -20°C, protected from light
Reconstituted
Refrigerate at 2-8°C, use within 2 weeks
Research compound for oncology studies
- •Research compound - not FDA approved
- •Primarily for in vitro/animal research
- •Not a substitute for cancer treatment
- •Requires specialized research protocols
Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.